Cancer drug developer obtains $32.5M in private placement

05/3/2013 | American City Business Journals

Celator Pharmaceuticals, a New Jersey-based firm specializing in cancer drugs, secured $32.5 million in a private placement led by Valence Life Sciences. Proceeds will go toward the late-stage trial of CPX-351 liposome injection, the company's lead drug candidate for secondary acute myeloid leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ